AU2012302042B2 - Compounds and compositions as c-kit kinase inhibitors - Google Patents

Compounds and compositions as c-kit kinase inhibitors Download PDF

Info

Publication number
AU2012302042B2
AU2012302042B2 AU2012302042A AU2012302042A AU2012302042B2 AU 2012302042 B2 AU2012302042 B2 AU 2012302042B2 AU 2012302042 A AU2012302042 A AU 2012302042A AU 2012302042 A AU2012302042 A AU 2012302042A AU 2012302042 B2 AU2012302042 B2 AU 2012302042B2
Authority
AU
Australia
Prior art keywords
pyridine
oxadiazol
imidazo
methyl
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012302042A
Other languages
English (en)
Other versions
AU2012302042A1 (en
Inventor
Xiaolin Li
Xiaodong Liu
Jon Loren
Valentina Molteni
Juliet Nabakka
Bao Nguyen
Hank Michael James Petrassi
Vince Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2012302042A1 publication Critical patent/AU2012302042A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: IRM LLC
Application granted granted Critical
Publication of AU2012302042B2 publication Critical patent/AU2012302042B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2012302042A 2011-09-01 2012-08-29 Compounds and compositions as c-kit kinase inhibitors Ceased AU2012302042B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01
US61/530,038 2011-09-01
PCT/US2012/052802 WO2013033167A1 (en) 2011-09-01 2012-08-29 Compounds and compositions as c-kit kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2012302042A1 AU2012302042A1 (en) 2014-04-17
AU2012302042B2 true AU2012302042B2 (en) 2016-03-31

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012302042A Ceased AU2012302042B2 (en) 2011-09-01 2012-08-29 Compounds and compositions as c-kit kinase inhibitors

Country Status (30)

Country Link
US (3) US8569283B2 (https=)
EP (1) EP2751104B1 (https=)
JP (1) JP6134319B2 (https=)
KR (1) KR101962495B1 (https=)
CN (1) CN103797011B (https=)
AP (1) AP2014007493A0 (https=)
AR (1) AR087753A1 (https=)
AU (1) AU2012302042B2 (https=)
BR (1) BR112014004560A2 (https=)
CA (1) CA2845169C (https=)
CL (1) CL2014000492A1 (https=)
CO (1) CO6900141A2 (https=)
CR (1) CR20140107A (https=)
CU (1) CU20140024A7 (https=)
EA (1) EA026152B1 (https=)
ES (1) ES2761332T3 (https=)
GT (1) GT201400034A (https=)
IL (1) IL231227A0 (https=)
MA (1) MA35460B1 (https=)
MX (1) MX339937B (https=)
PE (1) PE20140909A1 (https=)
PH (1) PH12014500372A1 (https=)
PL (1) PL2751104T3 (https=)
PT (1) PT2751104T (https=)
SG (1) SG2014014369A (https=)
TN (1) TN2014000068A1 (https=)
TW (1) TW201313717A (https=)
UY (1) UY34301A (https=)
WO (1) WO2013033167A1 (https=)
ZA (1) ZA201401175B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103797011B (zh) 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
UA125171C2 (uk) 2015-07-02 2022-01-26 Янссен Саєнсиз Айрленд Юсі Антибактеріальні сполуки
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
US20190256509A1 (en) * 2016-06-08 2019-08-22 Chrysalis, Inc. Histone demethylase inhibitors
JP2019518046A (ja) 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
US20200308169A1 (en) 2016-06-16 2020-10-01 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
KR20190121315A (ko) 2017-03-01 2019-10-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 병용 요법
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
WO2019090088A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
MA55976A (fr) * 2019-05-13 2022-03-23 Novartis Ag Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2021035788A1 (zh) 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 吡唑衍生物及其用途
US20220340564A1 (en) 2019-09-13 2022-10-27 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
TWI893032B (zh) 2019-12-13 2025-08-11 日商日本新藥股份有限公司 作為pdgf受體激酶抑制劑之化合物及組合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023534963A (ja) 2020-07-15 2023-08-15 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の結晶質形態
US11744823B2 (en) 2020-11-19 2023-09-05 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
MX2023010947A (es) 2021-03-16 2023-11-29 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
EP4423097A1 (en) 2021-10-28 2024-09-04 Janssen Sciences Ireland Unlimited Company Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
JP2025540958A (ja) * 2022-11-30 2025-12-17 ブループリント メディシンズ コーポレイション 蕁麻疹の治療のための野生型ｃ－ｋｉｔキナーゼ阻害剤としてのＮ－フェニル－ピラゾロ［１，５－Ａ］ピリジン－３－カルボキサミド誘導体
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
AU2023390239A1 (en) * 2022-12-07 2025-07-24 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025072330A1 (en) * 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025256552A1 (zh) * 2024-06-11 2025-12-18 上海翰森生物医药科技有限公司 吡唑类衍生物抑制剂、其制备方法和应用
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
WO2025259929A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058037A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
UA94570C2 (en) 2004-09-09 2011-05-25 Натко Фарма Лимитед Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
AU2011329233A1 (en) * 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
US20150051206A1 (en) 2011-09-01 2015-02-19 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CN103797011B (zh) 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
KR20140105433A (ko) 2011-09-01 2014-09-01 아이알엠 엘엘씨 Pdgfr 키나제 억제제로서의 화합물 및 조성물
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058037A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
TW201313717A (zh) 2013-04-01
SG2014014369A (en) 2014-09-26
JP2014525448A (ja) 2014-09-29
US20140031333A1 (en) 2014-01-30
KR101962495B1 (ko) 2019-03-26
KR20140075692A (ko) 2014-06-19
JP6134319B2 (ja) 2017-05-24
US8569283B2 (en) 2013-10-29
EA026152B1 (ru) 2017-03-31
AU2012302042A1 (en) 2014-04-17
ES2761332T3 (es) 2020-05-19
CA2845169C (en) 2022-04-19
US9023839B2 (en) 2015-05-05
CO6900141A2 (es) 2014-03-20
WO2013033167A1 (en) 2013-03-07
EP2751104A1 (en) 2014-07-09
UY34301A (es) 2013-04-05
CU20140024A7 (es) 2014-04-24
MX339937B (es) 2016-06-17
MX2014002484A (es) 2014-11-25
CL2014000492A1 (es) 2014-10-03
CN103797011A (zh) 2014-05-14
ZA201401175B (en) 2015-01-28
TN2014000068A1 (en) 2015-07-01
PH12014500372A1 (en) 2014-04-07
CR20140107A (es) 2014-05-02
BR112014004560A2 (pt) 2017-04-04
GT201400034A (es) 2015-02-19
US20140228347A1 (en) 2014-08-14
IL231227A0 (en) 2014-04-30
AR087753A1 (es) 2014-04-16
MA35460B1 (fr) 2014-09-01
PL2751104T3 (pl) 2020-04-30
PE20140909A1 (es) 2014-07-20
CN103797011B (zh) 2016-03-30
EA201490545A1 (ru) 2014-07-30
US20130059832A1 (en) 2013-03-07
AP2014007493A0 (en) 2014-03-31
CA2845169A1 (en) 2013-03-07
US8754071B2 (en) 2014-06-17
PT2751104T (pt) 2019-12-16
EP2751104B1 (en) 2019-09-25

Similar Documents

Publication Publication Date Title
AU2012302042B2 (en) Compounds and compositions as c-kit kinase inhibitors
AU2012300248B2 (en) Compounds and compositions as c-kit kinase inhibitors
AU2012302176A1 (en) Compounds and compositions as c-kit kinase inhibitors
AU2012302080A1 (en) Compounds and compositions as c-kit kinase inhibitors
AU2012301675A1 (en) Compounds and compositions as PDGFR kinase inhibitors
HK1193821B (en) Compounds and compositions as c-kit kinase inhibitors
HK1193821A (en) Compounds and compositions as c-kit kinase inhibitors
HK1193820B (en) Compounds and compositions as c-kit kinase inhibitors
HK1193820A (en) Compounds and compositions as c-kit kinase inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOVARTIS AG

Free format text: FORMER APPLICANT(S): IRM LLC

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired